1 / 15

Good Laboratory Practice CFR 21 Part 58

Good Laboratory Practice CFR 21 Part 58. A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International gclasby@promedica-intl.com 714-799-1617 x 25. GLP What It Is.

quade
Download Presentation

Good Laboratory Practice CFR 21 Part 58

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Good Laboratory PracticeCFR 21 Part 58 A Review for OCRA US RAC Study GroupSeptember 2005Ginger Clasby, MS Promedica Internationalgclasby@promedica-intl.com 714-799-1617 x 25

  2. GLPWhat It Is • Describes good practices for non-clinical lab studies that support research or marketing approvals for FDA-regulated products

  3. GLPGeneral Requirements • Appropriately qualified personnel • Adequate resources • Appropriate procedures for: • Sanitation, health precautions, clothing • Test protocol development, test methods • Data analysis, report development • Appropriately qualified study director • Quality assurance function

  4. GLPFacilities Requirements • Suitable size, construction, segregation • Animal care • Animal supplies • Test & control products maintained in a secure area • Operating “suite” • Specimen & data storage

  5. GLPEquipment Requirements • Appropriately designed • Adequate thru-put capacity • Appropriately located • Routinely maintained & calibrated

  6. GLPStandard Operating Procedures • Animal room prep • Animal care • Receipt, ID, storage, handling, mixing & sampling of test & control articles • Test system observations • Lab tests • Handling of moribund or dead animals • Necropsy or postmortem exams of animals

  7. GLPStandard Operating Procedures • Collection & ID of specimens • Histopathology • Data handling, storage & retrieval • Equipment maintenance & calibration • Transfer, proper placement & ID of animals

  8. GLPReagents & Solutions • Adequate labeling • Identity • Concentration • Storage requirements • Expiration date

  9. GLPTest & Control Articles • Adequate characterization • Proper receipt, storage, distribution • When mixed with a carrier, adequate methods to confirm • Mixture uniformity • Article concentration • Article stability

  10. GLPStudy Implementation • Written, approved protocol indicating test objectives & methods • Study conducted in accordance with protocol • Study monitoring to confirm protocol compliance • Appropriate labeling of specimens by test system, study, nature & collection date • Records of gross findings from postmortems available to pathologist for specimen histopathology

  11. GLPStudy Implementation • Standard data capture/recording requirements • Legibility • Permanence • Accountability • Changes

  12. GLPRecords & Reports • Final report of results • Study records & data methodically archived to facilitate expedient retrieval • Study documents • Raw data • Specimens • Protocols • QA inspections • Personnel training & qualifications • Calibration & maintenance records

  13. GLPRecords & Reports • Records retention (shortest of): • ≥ 2 yr after FDA marketing clearance • ≥ 5 yr after data submitted to FDA in support of marketing application • ≥ 2 yr after Sponsor decision not to proceed with marketing application • Wet specimens hold as long as viable • Records transferable with written FDA notification

  14. GLPFacility Disqualification • Grounds for disqualification: • Failure to comply with regulations & • Noncompliance adversely affects study validity & • Previous regulatory actions have been unsuccessful in modifying facility operations

  15. GLPReference Documents & Links (www.fda.gov/cder) • 21 CFR 58 – Good Laboratory Practice for Non-clinical Laboratory Studies • Div. of Scientific Investigations: Good Laboratory Practice www.fda.gov/cder/Offices/DSI/goodLabPractice.htm • BIMO Compliance Program Guidance 7348.808A: GLP Program www.fda.gov/ora/compliance_ref/bimo/7348_808A/Default.htm

More Related